All Stories

Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset

Alphabet’s Calico Life Sciences is inking a deal worth up to $571 million biobucks for the rights to investigational IL-11 directed therapeutics from Mabwell Bioscience, including a clinical-stage monoclonal antibody for age-related diseases.

Jun 26, 2025 - 23:05
 0
Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset
Alphabet’s Calico Life Sciences is inking a deal worth up to $571 million biobucks for the rights to investigational IL-11 directed therapeutics from Mabwell Bioscience, including a clinical-stage monoclonal antibody for age-related diseases.
Read More

Tags:

Previous Article

With thimerosal vote, RFK Jr.'s ACIP shows willingness to take on vaccine conven...

Next Article

RFK Jr.-appointed panel recommends flu shots be free of contested preservative

Related Posts

Candel sheds more light on successful late-stage trial of prostate cancer immunotherapy

Candel sheds more light on successful late-stage trial ...

May 23, 2025  0

Industry deeply disappointed as FDA puts cell and gene therapy chief on administrative leave

Industry deeply disappointed as FDA puts cell and gene ...

Jun 20, 2025  0

Fierce Biotech Fundraising Tracker '25: Allay accesses $57M series D; SpyGlass secures $75M series D

Fierce Biotech Fundraising Tracker '25: Allay accesses ...

Jun 5, 2025  0